Andere Sprachen Precigen, Inc.

Aktien

A2PZG1

US74017N1054

PGEN

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 14.05.2024			% 5 Tage	% 1. Jan.
1,37 ^USD	+1,48 %		-0,72 %	+2,24 %

24.04.	Precigen, Inc. präsentiert spätes Abstract zu Daten der zulassungsrelevanten Phase-2-Studie für PRGN- 2012 AdenoVerse Immuntherapie	CI
22.03.	Precigen-Aktien fallen nach Herabstufung durch JPMorgan	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Earnings Flash (PGEN) PRECIGEN Reports Q1 Revenue $1.1M, vs. Street Est of $1.5M	14.05.
Precigen to Present Late-breaking Abstract for Pivotal Phase 2 Study Data for PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Patients with Recurrent Respiratory Papillomatosis at the 2024 ASCO Annual Meeting	25.04.
Precigen, Inc. to Present Late-Breaking Abstract for Pivotal Phase 2 Study Data for PRGN- 2012 AdenoVerse Immunotherapy	24.04.
Precigen and Recurrent Respiratory Papillomatosis Foundation to Hold Inaugural International RRP Awareness Day on June 11th	28.03.
North American Morning Briefing : Tech in Focus on -2-	25.03.
Precigen Shares Fall After Downgrade From JPMorgan	22.03.
Precigen Reports Full Year 2023 Financial Results and Business Updates	20.03.
Precigen, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	19.03.
North American Morning Briefing : Stock Futures -2-	19.03.
Precigen to Participate in a Fireside Chat Hosted by Cantor Fitzgerald to Discuss PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis	12.03.
Precigen to Announce Fourth Quarter and Full Year 2023 Financial Results on March 19th	05.03.
Precigen to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference	06.02.
Precigen's Investigational RRP Therapy Gets Orphan Drug Designation in Europe	16.01.
Precigen Receives Orphan Drug Designation for PRGN-2012 for the Treatment of Recurrent Respiratory Papillomatosis from the European Commission	16.01.
Precigen, Inc. Receives Orphan Drug Designation for PRGN- 2012 for the Treatment of Recurrent Respiratory Papillomatosis from the European Commission	16.01.
Precigen Highlights Pipeline Updates to be presented at the 42nd Annual J.P. Morgan Healthcare Conference	09.01.
Precigen to Present at the 42nd Annual J.P. Morgan Healthcare Conference	18.12.
Precigen to Participate in the JMP Securities Hematology and Oncology Summit	29.11.
Precigen Q3 Net Loss Widens, Revenue Falls	09.11.
Precigen, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09.11.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Precigen, Inc.

Aktien

A2PZG1

US74017N1054

PGEN

Andere Sprachen

Filter